Stay updated on Dauno/Cytarabine ± Uproleselan in AML Clinical Trial
Sign up to get notified when there's something new on the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page.

Latest updates to the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 to the history and removed the government-funding notices along with the older Revision: v3.4.1.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded a government-funding notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check28 days agoChange DetectedA new revision entry on 2026-01-21 adds the 'Results Posted' item and introduces color-coded diffs (green for additions, red for deletions) across key sections, along with a 'Show glossary' option. The 2025-10-29 'Results Submitted' entry appears as a deletion in the history.SummaryDifference0.4%

- Check42 days agoChange DetectedRevision: v3.3.4 was added to the page history, replacing the previous v3.3.3 entry.SummaryDifference0.0%

- Check49 days agoChange DetectedThe record history shows the status shifted from 'No Results Posted' to 'Results Submitted', indicating that results have been submitted to ClinicalTrials.gov. This marks a substantive update to the study record's results status.SummaryDifference0.0%

- Check63 days agoChange DetectedFooter updates: added 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.0%

Stay in the know with updates to Dauno/Cytarabine ± Uproleselan in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page.